Sarepta Therapeutics (SRPT) Misses Q4 EPS by 237c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($3.58), $2.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $442.9 million versus the consensus estimate of $379.71 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Sprinklr Inc (CXM) PT Raised to $7.50 at Cantor Fitzgerald
• Economic activity increased modestly since early July - Beige Book